Sensus Healthcare, Inc. (SRTS) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue:: $3.4 million, down from $8.3 million year-over-year, primarily due to the absence of sales to the company's largest customer.

Gross Profit:: $1.0 million, with a gross margin of 29.2%, compared to 52.2% in the prior year, reflecting a shift in product mix and lower average selling prices.

Operating Expenses:: General and administrative expenses decreased to $2.0 million; selling and marketing expenses fell to $1.7 million; R&D expenses decreased to $1.6 million.

Net Loss:: $2.6 million, or $0.16 per share, consistent with the prior-year period.

Cash Position:: $18.3 million in cash with no debt, and inventory increased to $16.5 million.

2Strategic Updates and Business Highlights

CPT Code Implementation:: The introduction of dedicated CPT codes for superficial radiotherapy (SRT) as of January 1, 2026, is expected to enhance reimbursement clarity and drive customer adoption.

Customer Diversification:: The company shipped 14 SRT systems in Q1, including 10 direct sales and 4 under rental agreements, aiming to reduce historical customer concentration.

Recurring Revenue Focus:: The introduction of SensusLink aims to enhance workflow and create a scalable recurring revenue model tied to treatment activities.

Commercial Expansion:: Sensus Healthcare Financial Services was launched to provide flexible financing options for customers, improving conversion rates.

3Forward Guidance and Outlook

Revenue Expectations:: Q2 revenue is expected to be higher than Q1, with continued growth anticipated throughout 2026 as the sales pipeline strengthens.

Profitability Goal:: The company aims to achieve full-year profitability by leveraging improved reimbursement, a diversified customer base, and expanding recurring revenue streams.

4Challenges and Points of Concern

Customer Concentration:: The absence of sales to the largest customer, which previously accounted for significant revenue, poses a risk to revenue stability.

Revenue Decline:: Year-over-year revenue decreased significantly, raising concerns about the transition to a more diversified customer base.

Gross Margin Pressure:: The decline in gross margin due to product mix and lower average selling prices may affect profitability in the short term.

5Notable Q&A Insights

Customer Return Potential:: Management indicated that the largest customer not purchasing in Q1 is viewed as potential upside if they return, but they are not included in the current financial model.

Sales Cycle Impact:: The new CPT codes have led to increased interest and inquiries, with expectations of shorter sales cycles as practices gain confidence in reimbursement.

Pipeline Development:: The sales team is optimistic about converting leads generated from recent dermatology conferences into sales, with a focus on education and awareness of the new reimbursement codes.

Recurring Revenue Timeline:: Management believes that as education about SRT expands, adoption will increase, leading to a more predictable revenue stream, particularly through the SensusLink software. Overall, Sensus Healthcare is navigating a transitional phase with a focus on leveraging new reimbursement codes to drive customer adoption and recurring revenue, while also addressing challenges related to customer concentration and revenue decline.